Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Medicine Man Technologies's annualized net income for the quarter that ended in Jun. 2024 was $-55.7 Mil. Medicine Man Technologies's average shareholder tangible equity for the quarter that ended in Jun. 2024 was $-129.0 Mil. Therefore, Medicine Man Technologies's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2024 was N/A%.
The historical rank and industry rank for Medicine Man Technologies's Return-on-Tangible-Equity or its related term are showing as below:
SHWZ's Return-on-Tangible-Equity is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 10.21 * Ranked among companies with meaningful Return-on-Tangible-Equity only.
Medicine Man Technologies (OTCPK:SHWZ) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Medicine Man Technologies Return-on-Tangible-Equity Related Terms
Medicine Man Technologies Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Medicine Man Technologies's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medicine Man Technologies Return-on-Tangible-Equity Chart
SHWZ vs HEWA, RDGT, SSY: Return-on-Tangible-Equity Comparison
For the Pharmaceutical Retailers subindustry, Medicine Man Technologies's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medicine Man Technologies Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Medicine Man Technologies's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Medicine Man Technologies's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2024) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 0.00% mean?
Medicine Man Technologies (SHWZ) has a Return-on-Tangible-Equity of 0.00% as of Jun. 2024. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Medicine Man Technologies and its competitors.
Is Medicine Man Technologies' Return-on-Tangible-Equity too high?
Medicine Man Technologies' current Return-on-Tangible-Equity is 0.00%. Overall, Medicine Man Technologies has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Medicine Man Technologies' Return-on-Tangible-Equity compare to HEWA and RDGT?
Medicine Man Technologies' Return-on-Tangible-Equity of 0.00% can be compared against companies in the Healthcare Providers & Services industry. The industry median Return-on-Tangible-Equity is 10.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.21, based on 579 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Medicine Man Technologies and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medicine Man Technologies's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicine Man Technologies stock overvalued right now?
Medicine Man Technologies (SHWZ) has a current Return-on-Tangible-Equity of 0.00%. The current Return-on-Tangible-Equity is 0.00%. Medicine Man Technologies' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Medicine Man Technologies (SHWZ), the current Return-on-Tangible-Equity is 0.00% as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Medicine Man Technologies Inc is a vertically integrated multi-state cannabis operator focused on growth through expansion into existing and new markets. The Company's business involves the cultivation, manufacturing, distribution, and retail sale of cannabis and cannabis-related products. The Company sells products it manufactures and cultivates and a variety of other cannabis goods through wholly-owned retail stores, licensing arrangements, and/or third-party operators and retailers. Its operations are organized into three different segments: Retail, consisting of retail locations for sale of cannabis products; Wholesale, consisting of manufacturing, cultivation, and sale of both wholesale cannabis and non-cannabis products; and Other, consisting of all other income and expenses.
12GF Score
Get the complete analysis for SHWZ
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHWZ has been successfully added to your 
